What Are Mylan’s Key Growth Drivers in Fiscal 2019?
Is Pfizer or Mylan a Better Pharmaceutical Pick Right Now?(Continued from Prior Part)Performance in fiscal 2018In fiscal 2018, Mylan (MYL) reported revenues of $11.43 billion, a YoY decline of 4%. The company reported adjusted EPS of $4.58, a YoY